News & Events

Savara Pharmaceuticals / News & Events
02Nov, 2016

Savara Pharmaceuticals appoints David L. Lowrance as CFO

0 Comments
Austin, Texas – November 2, 2016 – Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today... Read More
18Jul, 2016

Savara Completes Acquisition of Serendex

0 Comments
Strengthens pipeline serving patients with rare respiratory diseases Austin, Texas – July 18, 2016 – Savara Pharmaceuticals, an emerging specialty... Read More
21Jun, 2016

Savara Pharmaceuticals Acquires Serendex Pharmaceuticals

0 Comments
Adds two orphan respiratory drugs to its growing pipeline Austin, Texas – June 21, 2016 Savara Pharmaceuticals, an emerging specialty... Read More
09Jun, 2016

Savara Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference

0 Comments
New York City – June 9, 2016 Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today... Read More
25May, 2016

First patient dosed in Savara’s pivotal trial for PAP

0 Comments
Savara’s phase II/III clinical trial of lead drug candidate Molgradex® for patients with pulmonary alveolar proteinosis (PAP) has included its... Read More
12May, 2016

Savara signs license agreement with Japanese partner

0 Comments
Savara signs license agreement with Japanese Nobelpharma Co. Ltd for future commercialisation of Molgradex® in Japan. With reference to earlier... Read More
01Mar, 2016

Savara Pharmaceuticals Completes $20 Million Round of Financing

0 Comments
Preparation underway for Phase 3 trial of AeroVanc for MRSA lung infection in people with cystic fibrosis Austin, TX –... Read More
23Feb, 2015

Savara Pharmaceuticals’ AeroVanc Meets Primary Endpoint of MRSA Reduction in Phase 2 Trial in People with Cystic Fibrosis

0 Comments
Trial also demonstrates strong trends in secondary clinical endpoints Austin, TX – February 23, 2015 Savara Pharmaceuticals announced today positive... Read More
06Oct, 2014

Savara Pharmaceuticals Raises $10 Million to Advance AeroVanc for MRSA Lung Infection in People with Cystic Fibrosis

0 Comments
Company Completes Enrollment in Phase 2 Clinical Trial Austin, TX – October 6, 2014 Savara Pharmaceuticals announced today that it... Read More
10Dec, 2013

Savara Pharmaceuticals Announces FDA Grant of Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Its Lead Product, AeroVanc

0 Comments
AUSTIN, TX – December 10, 2013 – Savara Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has... Read More
05Dec, 2013

Savara Pharmaceuticals Appoints Two New Members to Its Board of Directors

0 Comments
AUSTIN, TX – December 5, 2013 Savara Pharmaceuticals announced today that the company has appointed Dr. Joseph S. McCracken, DVM... Read More
17Oct, 2013

Cystic Fibrosis Foundation Therapeutics Provides Savara Pharmaceuticals $1.7 Million Award for Development of AeroVanc

0 Comments
AUSTIN, TX – October 17, 2013 Savara Pharmaceuticals announced today it has received a $1.7 million research award from Cystic... Read More
18Apr, 2013

Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients

0 Comments
AUSTIN, TX – April 18, 2013 Savara Pharmaceuticals announced today that the first patient has started study drug treatment in... Read More
20Mar, 2013

Savara Pharmaceuticals Completes Second Tranche of $16 Million Series B Financing to Advance Treatment of MRSA Lung Infection in Cystic Fibrosis Patients

0 Comments
Austin, TX, March 20, 2013 Savara Pharmaceuticals today announced that it has closed a $7.4 million second tranche of its... Read More
23Feb, 2013

Savara Pharmaceuticals Announces Formation of Clinical Advisory Board

0 Comments
Austin, TX, February 26, 2013 Savara Pharmaceuticals today announced the formation of its Clinical Advisory Board to provide clinical guidance... Read More
13Nov, 2012

Savara Pharmaceuticals’ AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients

0 Comments
Austin, TX, November 13, 2012 Savara Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted orphan... Read More
12Jun, 2012

Savara Pharmaceuticals Raises $8.6 Million in Series B Financing Round

0 Comments
Austin, TX, June 12, 2012 Savara Pharmaceuticals, an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of... Read More
12Jun, 2012

Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients

0 Comments
Austin, TX, June 12, 2012 Savara Pharmaceuticals, an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of... Read More
Back to Top